Stay up to date on news concerning LabShares, our members and the Boston Biotech industry!
NEWTON, Mass.--(BUSINESS WIRE)--LabShares Newton celebrated today the opening of 19,000 square feet of new incubator lab space and expects to open another 6,000-foot lab in September. LabShares’ new space incorporates 12 private suites, 15 lab benches in the open lab, and a comprehensive set of shared resources and equipment. All private suites have already been committed to a group of exciting startup biotechs. In total, LabShares operates over 40,000 square feet of shared lab and office space for over 30 member companies.
LabShares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research
April 28, 2020
LabShares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies, DOTS, Mantle Biotech, and NowAware, will receive three months of free access to a lab bench in LabShares fully-equipped BL2 lab space
Newton's First Life Sciences Incubator Set To Expand
November 2, 2018
Longtime biotech executive Jeff Behrens ventured out of the C-Suite earlier this year, opening the first life sciences-focused incubator in Newton. Now he's expanding the project amid broader demand for shared lab space.
December 9, 2021
BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and LabShares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge Park in Newton, Massachusetts, with an additional 25,000 square feet of space, bringing LabShares’ total leased premises at the complex to approximately 40,000 square feet.
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
August 19, 2019
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.